Is Docusign Stock Worth Buying as IAM Growth Meets Liquidity Risks?

Docusign's Intelligent Agreement Management platform reached 15.1% of ARR in fiscal Q2 2027, up from 12.6% in Q1, while fiscal 2027 EPS estimates rose 2.5% over four weeks to $4.59 and non-GAAP operating margin expanded 180bps year over year to 31.6%. DOCU trades at 14.2x forward EPS, below its 29.4x sub-industry, 20.4x sector and 19.5x S&P 500 benchmarks, and repurchased $306.5 million of shares with $2.1 billion remaining authorized. Positives are offset by a 0.64 current ratio, despite $973.1 million of cash and investments and no debt, and by pricing risks from Adobe, Dropbox and lower-cost or AI-enabled alternatives.

Analysis

The investable question is not whether DOCU can attach IAM to its base, but whether the attachment raises net revenue retention enough to offset a structurally lower standalone-signature pricing umbrella. The reported margin improvement is less clean than it appears because capitalized software costs defer expense recognition; investors should focus on cash conversion, sales-and-marketing efficiency, and IAM-specific renewal/expansion cohorts rather than headline non-GAAP margin. If IAM becomes a workflow system of record, DOCU can earn a higher retention multiple; if it remains a feature bundle, ADBE's distribution advantage makes the valuation discount deserved.

Near term (one to three months), ongoing repurchases can mechanically support EPS and dampen downside, but they do not establish organic demand quality. The working-capital headline is not a funding risk given net cash and subscription-related deferred revenue, yet it limits the usefulness of the current ratio as a bearish catalyst; the more relevant liquidity risk is deploying buyback capacity while growth decelerates and stock-based compensation remains elevated. Watch next-quarter IAM ARR mix, total billings/RPO growth, and free-cash-flow conversion: a deceleration in any two would likely trigger multiple compression despite EPS beats.

Contrarian view: the market may be underestimating the strategic value of agreement data and post-signature workflow, but it is also likely over-crediting the reported IAM mix before disclosure of incremental ACV, gross retention, and attach economics. ADBE is the principal competitive hedge rather than DBX: Acrobat's enterprise installed base can bundle acceptable functionality at near-zero incremental procurement friction. The thesis is falsified if DOCU cannot sustain margin while reaccelerating billings, or if management relies on price concessions to lift IAM adoption over the next two earnings prints.

Key Decisions for Investors

• Maintain a watch-list long in DOCU; initiate only after the next earnings release confirms IAM expansion alongside stable-to-improving billings/RPO growth and free-cash-flow conversion. Target a 6-12 month rerating if IAM demonstrates incremental monetization; exit on material pricing pressure or a guide-down in subscription growth.
• For a market-neutral expression, consider long DOCU / short ADBE in equal beta only after DOCU provides IAM cohort or attach-rate disclosure that supports durable expansion. The payoff is DOCU multiple convergence, but stop out if ADBE demonstrates accelerating Acrobat Sign adoption or DOCU's billings growth trails ADBE's digital-experience growth for two quarters.
• Do not short DOCU solely on the current-ratio statistic: net cash and recurring billings make it a weak insolvency signal, while the remaining repurchase authorization is a meaningful technical bid over the next several quarters.
• Set an earnings alert for IAM mix growth without corresponding total subscription growth. That outcome would indicate cannibalization/repackaging rather than new wallet share and is the cleanest trigger for a tactical DOCU short or long ADBE / short DOCU pair.